{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:39:30Z","timestamp":1790624370134,"version":"4.1.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020124","name":"Seagen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020124","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.ctrv.2023.102653","type":"journal-article","created":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T23:07:59Z","timestamp":1699312079000},"page":"102653","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Pharmacotherapy for leptomeningeal disease in breast cancer"],"prefix":"10.1016","volume":"122","author":[{"given":"Rupert","family":"Bartsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna J.","family":"Jerzak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Larrouquere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volkmar","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Le Rhun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2023.102653_b0005","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2023.102653_b0010","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1200\/JCO.2009.25.9820","article-title":"Metastatic behavior of breast cancer subtypes","volume":"28","author":"Kennecke","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102653_b0015","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1186\/s12885-019-6311-z","article-title":"The clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer","volume":"19","author":"Wang","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2023.102653_b0020","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s11060-018-2790-z","article-title":"Determinants of prolonged survival for breast cancer patient groups with leptomeningeal metastasis (LM)","volume":"138","author":"Niwi\u0144ska","year":"2018","journal-title":"J Neurooncol"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102653_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101624","article-title":"Leptomeningeal metastasis from solid tumours: EANO\u2013ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"8","author":"Le Rhun","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2023.102653_b0030","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/neuonc\/noaa298","article-title":"Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors","volume":"23","author":"Le Rhun","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ctrv.2023.102653_b0035","first-page":"579","article-title":"Intracranial metastases from systemic cancer","volume":"19","author":"Posner","year":"1978","journal-title":"Adv Neurol"},{"key":"10.1016\/j.ctrv.2023.102653_b0040","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1634\/theoncologist.2018-0200","article-title":"Clinicopathological and treatment-associated prognostic factors in patients with breast cancer leptomeningeal metastases in relation to tumor biology","volume":"23","author":"Griguolo","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2023.102653_b0045","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clbc.2016.07.002","article-title":"Characteristics and outcomes of patients with breast cancer with leptomeningeal metastasis","volume":"17","author":"Morikawa","year":"2017","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ctrv.2023.102653_b0050","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejca.2018.02.032","article-title":"Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis","volume":"95","author":"Bonneau","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2023.102653_b0055","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s11060-013-1175-6","article-title":"Breast cancer and leptomeningeal disease (LMD): hormone receptor status influences time to development of LMD and survival from LMD diagnosis","volume":"114","author":"Yust-Katz","year":"2013","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ctrv.2023.102653_b0060","doi-asserted-by":"crossref","first-page":"iv84 -iv99","DOI":"10.1093\/annonc\/mdx221","article-title":"EANO-ESMO clinical practice guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours","volume":"28","author":"Le Rhun","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2023.102653_b0065","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.breast.2017.07.015","article-title":"Treatment and prognosis of leptomeningeal disease secondary to metastatic breast cancer: a single-centre experience","volume":"36","author":"Kingston","year":"2017","journal-title":"Breast"},{"key":"10.1016\/j.ctrv.2023.102653_b0070","doi-asserted-by":"crossref","first-page":"2027 -","DOI":"10.1200\/JCO.2022.40.16_suppl.2027","article-title":"Changing recognition of breast cancer\u2013related leptomeningeal disease and response to therapy: a retrospective single institution review","volume":"40","author":"Wallace","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102653_b0075","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2023.102653_b0080","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s11060-011-0592-7","article-title":"Clinicopathological features of breast cancers predict the development of leptomeningeal metastases: a case-control study","volume":"105","author":"Le Rhun","year":"2011","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ctrv.2023.102653_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102046","article-title":"Intrathecal administration of anti-HER2 treatment for the treatment of meningeal carcinomatosis in breast cancer: a metanalysis with meta-regression","volume":"88","author":"Zagouri","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2023.102653_b0090","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1002\/ijc.34135","article-title":"Leptomeningeal metastases in patients with human epidermal growth factor receptor 2 positive breast cancer: real-world data from a multicentric European cohort","volume":"151","author":"Ratosa","year":"2022","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2023.102653_b0095","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s10549-011-1682-0","article-title":"Leptomeningeal metastases from breast cancer: intrinsic subtypes may affect unique clinical manifestations","volume":"129","author":"Lee","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2023.102653_b0100","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1200\/JCO.22.01148","article-title":"Randomized phase II trial of proton craniospinal irradiation versus photon involved-field radiotherapy for patients with solid tumor leptomeningeal metastasis","volume":"40","author":"Yang","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102653_b0105","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1001\/jamaoncol.2022.7364","article-title":"Assessment of phase 3 randomized clinical trials including patients with leptomeningeal disease: a systematic review","volume":"9","author":"Sharma","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2023.102653_b0110","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1158\/1078-0432.CCR-19-3258","article-title":"ANG1005, a brain-penetrating peptide-drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases","volume":"26","author":"Kumthekar","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2023.102653_b0115","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11060-013-1092-8","article-title":"A retrospective case series of 103 consecutive patients with leptomeningeal metastasis and breast cancer","volume":"113","author":"Le Rhun","year":"2013","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ctrv.2023.102653_b0120","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/neuonc\/noz201","article-title":"Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer","volume":"22","author":"Le Rhun","year":"2020","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ctrv.2023.102653_b0125","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1200\/JCO.2021.39.15_suppl.1044","volume":"39","author":"Stringer-Reasor","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102653_b0130","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41523-023-00519-0","article-title":"Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan","volume":"9","author":"Alder","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.ctrv.2023.102653_b0135","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10549-019-05309-6","article-title":"Phase II study of irinotecan and temozolomide in breast cancer patients with progressing central nervous system disease","volume":"177","author":"Melisko","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2023.102653_b0140","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1158\/1078-0432.CCR-18-3502","article-title":"Phase I study of intermittent high-dose lapatinib alternating with capecitabine for HER2-positive breast cancer patients with central nervous system metastases","volume":"25","author":"Morikawa","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2023.102653_b0145","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/neuonc\/noac180","article-title":"Phase II study of intrathecal administration of trastuzumab in patients with HER2-positive breast cancer with leptomeningeal metastasis","volume":"25","author":"Oberkampf","year":"2023","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ctrv.2023.102653_b0150","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s10549-014-3054-z","article-title":"Leptomeningeal disease and breast cancer: the importance of tumor subtype","volume":"146","author":"Abouharb","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2023.102653_b0155","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1016\/j.ejca.2004.08.012","article-title":"The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study","volume":"40","author":"Boogerd","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2023.102653_b0160","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/s41591-020-0918-0","article-title":"Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis","volume":"26","author":"Brastianos","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2023.102653_b0165","doi-asserted-by":"crossref","first-page":"5954","DOI":"10.1038\/s41467-021-25859-y","article-title":"Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis","volume":"12","author":"Brastianos","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2023.102653_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100150","article-title":"Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life database","volume":"6","author":"Carausu","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2023.102653_b0175","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s11060-010-0524-y","article-title":"Meningeal carcinomatosis in breast cancer: prognostic factors and outcome","volume":"104","author":"de Azevedo","year":"2011","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ctrv.2023.102653_b0180","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s10549-019-05170-7","article-title":"Clinical outcomes of breast leptomeningeal disease treated with intrathecal trastuzumab, intrathecal chemotherapy, or whole brain radiation therapy","volume":"175","author":"Figura","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2023.102653_b0185","doi-asserted-by":"crossref","first-page":"7935","DOI":"10.1002\/cam4.3422","article-title":"Intra-CSF topotecan in treatment of breast cancer patients with leptomeningeal metastases","volume":"9","author":"Jaeckle","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.ctrv.2023.102653_b0190","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/neuonc\/noac195","article-title":"A phase I\/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: safety, efficacy, and cerebrospinal fluid pharmacokinetics","volume":"25","author":"Kumthekar","year":"2023","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ctrv.2023.102653_b0195","doi-asserted-by":"crossref","first-page":"S504","DOI":"10.1016\/j.annonc.2021.08.603","article-title":"320P Prognostic role of meningeal carcinomatosis in breast cancer","volume":"32","author":"Meneguetti","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2023.102653_b0200","doi-asserted-by":"crossref","first-page":"e002473","DOI":"10.1136\/jitc-2021-002473","article-title":"Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers","volume":"9","author":"Naidoo","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2023.102653_b0205","doi-asserted-by":"crossref","first-page":"ii123","DOI":"10.1093\/neuonc\/noaa215.515","article-title":"NCMP-03. Intrathecal trastuzumab treatment of HER-2 positive leptomeningeal breast cancer: The University of Michigan experience","volume":"22","author":"Peters","year":"2020","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ctrv.2023.102653_b0210","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s10549-022-06595-3","article-title":"Clinical factors and association with treatment modalities in patients with breast cancer and brain metastases who develop leptomeningeal metastases","volume":"193","author":"Puri","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2023.102653_b0215","doi-asserted-by":"crossref","first-page":"5310","DOI":"10.1158\/1078-0432.CCR-20-1764","article-title":"A phase II study of abemaciclib in patients with brain metastases secondary to hormone receptor-positive breast cancer","volume":"26","author":"Tolaney","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2023.102653_b0220","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/s12885-015-1290-1","article-title":"A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis","volume":"15","author":"Wu","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2023.102653_b0225","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11060-012-0879-3","article-title":"Phase II trial of temozolomide for leptomeningeal metastases in patients with solid tumors","volume":"109","author":"Segura","year":"2012","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ctrv.2023.102653_b0230","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41523-023-00584-5","article-title":"Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and\/or leptomeningeal disease (ROSET-BM)","volume":"9","author":"Niikura","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.ctrv.2023.102653_b0235","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/neuonc\/noz024","article-title":"The RANO Leptomeningeal Metastasis Group proposal to assess response to treatment: lack of feasibility and clinical utility and a revised proposal","volume":"21","author":"Le Rhun","year":"2019","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ctrv.2023.102653_b0240","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv048","article-title":"Annual Report to the Nation on the Status of Cancer, 1975\u20132011, Featuring incidence of breast cancer subtypes by race\/ethnicity, poverty, and state","volume":"107","author":"Kohler","year":"2015","journal-title":"J Natl Cancer Inst."},{"key":"10.1016\/j.ctrv.2023.102653_b0245","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/cam4.4469","article-title":"Characteristics of metastasis and survival between male and female breast cancer with different molecular subtypes: a population-based observational study","volume":"11","author":"Fang","year":"2022","journal-title":"Cancer Med"},{"key":"10.1016\/j.ctrv.2023.102653_b0250","first-page":"161","article-title":"Biological subtypes and survival outcomes in breast cancer patients with brain metastases in the targeted therapy era","volume":"5","author":"Bastos","year":"2018","journal-title":"Neurooncol Pract"},{"key":"10.1016\/j.ctrv.2023.102653_b0255","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1158\/1078-0432.CCR-06-2854","article-title":"The blood-brain barrier and cancer: transporters, treatment, and Trojan horses","volume":"13","author":"Deeken","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2023.102653_b0260","doi-asserted-by":"crossref","first-page":"PD4-02","DOI":"10.1158\/1538-7445.SABCS21-PD4-02","article-title":"Abstract PD4-02: Safety and efficacy of a tucatinib-trastuzumab-capecitabine regimen for treatment of leptomeningeal metastasis (LM) in HER2-positive breast cancer: results from TBCRC049, a phase 2 non-randomized study","volume":"82","author":"Murthy","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2023.102653_b0265","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/01.cad.0000236313.50833.ee","article-title":"Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier","volume":"18","author":"Stemmler","year":"2007","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ctrv.2023.102653_b0270","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2023.102653_b0275","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/s41591-022-01935-8","article-title":"Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial","volume":"28","author":"Bartsch","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2023.102653_b0280","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/neuonc\/noac144","article-title":"Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: the DEBBRAH trial","volume":"25","author":"P\u00e9rez-Garc\u00eda","year":"2023","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ctrv.2023.102653_b0285","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1080\/14737175.2016.1202761","article-title":"Blood-brain barrier, cytotoxic chemotherapies and glioblastoma","volume":"16","author":"Dr\u00e9an","year":"2016","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.ctrv.2023.102653_b0290","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41392-017-0004-3","article-title":"Controlled drug delivery vehicles for cancer treatment and their performance","volume":"3","author":"Senapati","year":"2018","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ctrv.2023.102653_b0295","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cpt.2188","article-title":"Antigen mass may influence trastuzumab concentrations in cerebrospinal fluid after intrathecal administration","volume":"110","author":"Le Tilly","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ctrv.2023.102653_b0300","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/s41591-022-02170-x","article-title":"Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results","volume":"29","author":"Glitza Oliva","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2023.102653_b0305","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10549-021-06246-z","article-title":"Leptomeningeal metastasis in ER + HER2- advanced breast cancer patients: a review of the cases in a single institute over a 15-year period","volume":"189","author":"Watanabe","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2023.102653_b0310","doi-asserted-by":"crossref","first-page":"S509","DOI":"10.1016\/j.annonc.2021.08.613","article-title":"330TiP Trastuzumab deruxtecan (T-DXd; DS-8201) in HER2-positive (HER2+) and HER2-low expressing (HER-LE) metastatic breast cancer (MBC) with brain metastases (BM) and\/or leptomeningeal carcinomatosis (LMC): DEBBRAH","volume":"32","author":"Vaz Batista","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2023.102653_b0315","doi-asserted-by":"crossref","first-page":"TPS1099","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS1099","article-title":"Trial in progress: Phase I\/II study of radiation therapy followed by intrathecal trastuzumab\/pertuzumab in the management of HER2+ breast leptomeningeal disease","volume":"39","author":"Ahmed","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737223001469?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737223001469?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:32:38Z","timestamp":1759656758000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737223001469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":63,"alternative-id":["S0305737223001469"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2023.102653","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacotherapy for leptomeningeal disease in breast cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2023.102653","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102653"}}